Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the toxicity and tolerance of Myocet® in children
and adolescents with refractory or relapsed malignant glioma, with a dose diminished of 20%
of the dose recommended for adults and a dose recommended for adults, administered in single
dose in 1-hour perfusion each 21 days.
Other purposes are to determine the recommended dose of Myocet and to assess the response to
drug. Pharmacokinetics of doxorubicin (free and encapsulated forms) and its metabolite
doxorubicinol during 72 hours after Myocet administration will also be studied.